Investment
Features
FeesSafety
Academy
More
Pluang+

Compare INNIO N.V. Ordinary Shares (INIO) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance

INNIO N.V. Ordinary SharesTrade
Nuvation Bio Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

INNIO N.V. Ordinary Shares vs Nuvation Bio Inc. Class A Common Stock — how do they compare? INNIO N.V. Ordinary Shares trades at $16.22 (market cap $13.73B), while Nuvation Bio Inc. Class A Common Stock trades at $4.72 (market cap $1.66B). The key difference: INNIO N.V. Ordinary Shares is far larger — about 8.3× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Nuvation Bio Inc. Class A Common Stock for 6 Days on average.

INIONUVB
Market Cap
$13.73B$1.66B
Volume
5,012,1957,608,075
Sector
IndustrialsHealth
52-Week High
$41.13$9.54
52-Week Low
$16.50$3.41
Typical Hold Time
0 Days6 Days
Enterprise Value
$15.39B$1.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

INNIO N.V. Ordinary Shares

No Aura AI signal available yet.

Nuvation Bio Inc. Class A Common Stock

Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.

Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INIO
100% Buy0% Sell
Avg holding period · 0 Days
NUVB

No sentiment data available yet.

About INNIO N.V. Ordinary Shares

INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.

Read more on INIO →

About Nuvation Bio Inc. Class A Common Stock

Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.

Read more on NUVB →